Eli Lilly (LLY) Notes Payables (2009 - 2014)

Eli Lilly (LLY) has reported Notes Payables for 6 consecutive years, with $1.0 billion the latest figure, recorded in Q1 2014.

• Notes Payables for Q1 2014 came in at $1.0 billion, down 2.72% year-over-year; the trailing twelve-month figure through Mar 2014 was $1.0 billion (down 2.72% YoY), and the FY2013 annual result was $1.0 billion, up 8409.24% from the prior year.
• Notes Payables was $1.0 billion for Q1 2014 at Eli Lilly, down from $1.0 billion in the prior quarter.
• Over five years, Notes Payables peaked at $1.6 billion in Q3 2011 and troughed at $9.1 million in Q2 2012.
• Average Notes Payables over 5 years is $667.6 million, with a median of $578.0 million recorded in 2010.
• Year-over-year, Notes Payables slumped 99.44% in 2012 and surged 11143.96% in 2013.
• Over 5 years, Notes Payables stood at $156.0 million in 2010, then soared by 875.83% to $1.5 billion in 2011, then plunged by 99.22% to $11.9 million in 2012, then soared by 8409.24% to $1.0 billion in 2013, then decreased by 1.24% to $1.0 billion in 2014.
• Per Business Quant data, the three most recent Notes Payables figures were $1.0 billion in Q1 2014, $1.0 billion in Q4 2013, and $1.0 billion in Q2 2013.